Barclays PLC Acquires 84,563 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Barclays PLC increased its position in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 104.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 165,484 shares of the company's stock after acquiring an additional 84,563 shares during the quarter. Barclays PLC owned approximately 0.21% of Kura Oncology worth $3,234,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of KURA. nVerses Capital LLC acquired a new position in shares of Kura Oncology in the 3rd quarter valued at $25,000. Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at about $146,000. Erste Asset Management GmbH acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at about $215,000. Bellevue Group AG raised its stake in shares of Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company's stock valued at $266,000 after purchasing an additional 3,600 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at about $268,000.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA remained flat at $8.28 during mid-day trading on Friday. 815,081 shares of the company traded hands, compared to its average volume of 1,789,926. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $643.85 million, a P/E ratio of -3.51 and a beta of 0.78. Kura Oncology, Inc. has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The firm's 50-day simple moving average is $8.49 and its 200 day simple moving average is $14.60.

Insider Buying and Selling at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,255 shares of company stock worth $100,739. 5.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Kura Oncology from $37.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. BTIG Research cut shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. Bank of America decreased their target price on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, November 22nd. Scotiabank decreased their target price on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $27.13.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.